Reliance Global Adopts Poison Pill to Block Activist GNK Holdings
EZRA sits 61% above its 52-week low of $1.75 on light trading volume (0.1× avg).
Summary
Reliance Global Group adopted a one-year poison pill with a 15% trigger, exempting CEO Ezra Beyman and White Lion Capital, in response to GNK Holdings' recent 9.56% activist stake.
Key Events · Corporate Governance and Compliance · EZRA
-
Poison Pill Adopted
Board unanimously adopted a one-year stockholder rights plan with a 15% trigger threshold, expiring September 3, 2027.
-
CEO and Family Exempted
CEO Ezra Beyman, his immediate family, and entities they control are designated Exempt Persons, shielding them from the plan's dilution.
-
White Lion Carve-Out
The plan explicitly exempts shares acquired under White Lion Capital's existing ELOC agreement, protecting the company's primary financing source.
-
Activist Response
The plan follows GNK Holdings' disclosure of a 9.56% activist stake on August 27, 2026, and appears designed to block further accumulation.
Analysis · EZRA · Finance
Reliance Global Group adopted a one-year stockholder rights plan with a 15% trigger threshold, a direct response to GNK Holdings' 9.56% activist stake disclosed just days ago. The plan exempts CEO Ezra Beyman and his family, and carves out White Lion Capital's existing equity line, but would severely dilute any acquirer crossing 15% without board approval. For a company trading near its 52-week low with a market cap under $3 million and facing Nasdaq delisting risk, this is a defensive move to protect the board's control during the Altruis sale process and any potential takeover interest.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EZRA was trading at $2.82 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $1.75 to $78.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.